Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology

Adriana Maria Porro, Günter Hans Filho, Claudia Giuli Santi, Adriana Maria Porro, Günter Hans Filho, Claudia Giuli Santi

Abstract

Pemphigus are intraepidermal autoimmune bullous dermatoses that occur with lesions on the skin and / or mucous membranes. The most frequent types are pemphigus vulgaris and pemphigus foliaceus (classic and endemic). This consensus aims to present a complete and updated review of the treatment of these two more frequent forms of pemphigus, based on the literature and the personal experience of the authors. In moderate and severe cases of pemphigus vulgaris and foliaceus, systemic corticosteroid therapy (prednisone or prednisolone) is the treatment of choice. Adjuvant drugs, usually immunosuppressive drugs (azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide) may be prescribed as corticosteroid sparers in refractory cases or with contraindications to corticosteroids to minimize side effects. In severe and nonresponsive cases, corticosteroids in the form of intravenous pulse therapy, immunoglobulin and plasmapheresis / immunoadsorption can be administered. Immunobiological drugs, particularly rituximab, appear as a promising alternative. For milder cases, smaller doses of oral corticosteroid, dapsone and topical corticosteroids are options. At the end flowcharts are presented as suggestions for a therapeutic approach for patients with pemphigus vulgaris and pemphigus foliaceus.

Conflict of interest statement

Conflict of interest: None.

Figures

Figure 1
Figure 1
Treatment algorithm for pemphigus vulgaris PV: pemphigus vulgaris; AZA: azathioprine; MMF: mycophenolate mofetil; IVIG: intravenous immunoglobulin PV only in mucous membrane: Mild: only in oral mucosa/ Moderate: extensive lesions in oral mucosa/ Severe: lesions in oral mucosa and others (for example, esophagus, larynx) PV mucocutaneous: Mild: 10% of BSA: BSA: body surface area (1% means the sum of injured areas corresponding to the palmar surface of the hand with the five digits) * This severity rating is not definitive and aims to provide initial guidance. Each case should be evaluated individually, including considering the speed of onset and progression of the lesions, comorbidities, contraindications to the use of corticosteroids and response to the treatment applied. ** Prednisone can be replaced by oral prednisolone
Figure 2
Figure 2
Pemphigus foliaceus - treatment algorithm FS - fogo selvagem; BSA - body surface area (1% means the sum of injured areas corresponding to the palm area); CS - corticosteroid; DDS -diamino-diphenil-sulfone or dapsone; AZA -azathioprine; MMF - mycophenolate mofetil;MTX - methotrexate; IVIg -intravenous immunoglobulin.

References

    1. Kridin K, Sagi SZ, Bergman R. Mortality and cause of death in Israeli patients with pemphigus. Acta Derm Venereol. 2017;97:607–611.
    1. Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the USA. Br J Dermatol. 2016;174:1290–1298.
    1. Di Zenzo G, Amber KT, Sayar BS, Müller EJ, Borradori L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016;38:57–74.
    1. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–468.
    1. Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin Exp Dermatol. 2011;36:703–707.
    1. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis) Clin Dermatol. 2011;29(4):432–436.
    1. Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22:699–704.
    1. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66:255–270.
    1. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61–73.
    1. Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol. 2018;54:1–25.
    1. Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016 May 23;11:175–197.
    1. Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clin Dermatol. 2016;34:205–213.
    1. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429–452.
    1. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30:78–83.
    1. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132:203–212.
    1. Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S, Yayli S, et al. Pemphigus. S2 guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2015;29:405–414.
    1. Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133–142.
    1. Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: Associations and management guidelines: Facts and controversies. Clin Dermatol. 2013;31:382–390.
    1. Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177:1170–1201.
    1. Rao PN, Lakshmi TS. Pulse therapy and its modifications in pemphigus: a six year study. Indian J Dermatol Venereol Leprol. 2003;69:329–333.
    1. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–628.
    1. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7:221–228.
    1. Frew JW, Martin LK, Murrell DF. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29:599–606.
    1. Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: A systematic review and meta- analysis. J Am Acad Dermatol. 2015;73:264–271.
    1. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122–1124.
    1. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27:1285–1292.
    1. Chaidemenos G, Apalla Z, Koussidou T, Papagarifallou I, Ioannides D. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. J Eur Acad Dermatol Venereol. 2011;25:206–210.
    1. Committee for Guidelines for the Management of Pemphigus Disease. Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, et al. Japanese guidelines for the management of pemphigus. J Dermatol. 2014;41:471–486.
    1. Olejarz W, Bryk D, Zapolska-Downar D. Mycophenolate mofetil-a new atheropreventive drug? Acta Pol Pharm. 2014;71:353–361.
    1. Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. Adv Ther. 2016;33:910–958.
    1. Vyas N, Patel NS, Cohen GF. Mycophenolate mofetil as a first-line steroid sparing agent in the treatment of pemphigus vulgaris. J Drugs Dermatol. 2013;12:210–216.
    1. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64:903–908.
    1. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo controlled trial. J Invest Dermatol. 2010;130:2041–2048.
    1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immuneglobulin. N Engl J Med. 2006;355:1772–1779.
    1. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850–2858.
    1. Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris:Rituximab and beyond. J Am Acad Dermatol. 2016;74:746–753.
    1. Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–932.
    1. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–2040.
    1. Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, Ortonne N, Hüe S, Paul M, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151:200–203.
    1. Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol. 2018;54:131–138.
    1. Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–622.
    1. Heelan K, Al-Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150:703–708.
    1. Kanwar AJ, Vinay K, Sawatkar GU, Dogra S, Minz RW, Shear NH, et al. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients:a randomized comparative observer blinded study. Br J Dermatol. 2014;170:1341–1349.
    1. Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29:777–782.
    1. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
    1. Londhe PJ, Kalyanpad Y, Khopkar US. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Indian J Dermatol Venereol Leprol. 2014;80:300–305.
    1. Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25–31.
    1. Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–852.
    1. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2) J Am Acad Dermatol. 2007;56:e55–e79.
    1. Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
    1. Murrell DF, Peña S, Joly P, et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol. 2018 Epub ahead of print.
    1. Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–411.
    1. Shaik F, Botha J, Aboobaker J, Mosam A. Corticosteroid /cyclophosphamide pulse treatment in south African patients with pemphigus. Clin Exp Dermatol. 2010;35:245–250.
    1. Zhao CY, Murrell DF. Pemphigus Vulgaris: An Evidence-Based Treatment Update. Drugs. 2015;75:271–284.
    1. Sharma VK, Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659–664.
    1. Rose E, Wever S, Zilliken D, Linse R, Haustein UF, Bröcker EB, et al. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges. 2005;3:200–206.
    1. Sethy PK, Khandpur S, Sharma VK. Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris. Indian J Dermatol Venereol Leprol. 2009;75:476–482.
    1. Parmar NV, Kanwar AJ, Minz RW, Parsad D, Vinay K, Tsuruta D, et al. Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study. Indian J Dermatol Venereol Leprol. 2013;79:70–76.
    1. Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161:723–731.
    1. Baum S, Greenberger S, Samuelov L, Solomon M, Lyakhovitsky A, Trau H, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22:83–87.
    1. Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169:916–921.
    1. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol. 2009;10:383–396.
    1. Baum S, Debby A, Gilboa S, Trau H, Barzilai A. Efficacy of Dapsone in the treatment of pemphigus vulgaris: a single-center case study. Dermatology. 2016;232:578–585.
    1. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85–92.
    1. Chaigne B, Mouthon L. Mechanisms of action of intravenous immunoglobulin. Transfus Apher Sci. 2017;56:45–49.
    1. Svecova D. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol. 2016;57:141–144.
    1. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.
    1. Sinha AA, Hoffman MB, Janicke EC. Pemphigus vulgaris: approach to treatment. Eur J Dermatol. 2015;25:103–113.
    1. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein- reactive autoantibodies by immunoadsorption. Dermatology. 2006;212:177–187.
    1. Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial. 2012;16:311–320.
    1. Gach JE, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol. 2004;29:271–272.
    1. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
    1. Czernik A, Bystryn JC. Kinetics of response to conventional treatment in patients with pemphigus vulgaris. Arch Dermatol. 2008;144:682–683.
    1. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009:CD006263.
    1. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42:422–427.
    1. Almugairen N, Hospital V, Bedane C, Duvert-Lehembre S, Picard D, Tronquoy AF, et al. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69:583–588.
    1. Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta- Analysis. Am J Clin Dermatol. 2014;15:503–515.
    1. Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989;20:657–669.
    1. Amagai M. Pemphigus. In: Bolognia JL, Lorizzo JO, Schaffer JV, editors. Dermatology. 2nd ed. Vol. 1. China: Elsevier Saunders; 2012. pp. 461–474.
    1. Hans-Filho G, Cunha PR. Fogo Selvagem (Endemic Pemphigus Foliaceus) In: Tyring SK, Lupi O, Hengge UR, editors. Tropical Dermatology. 2nd ed. Edinburgh: Elsevier; 2017. pp. 427–432.
    1. Hans-Filho G, Aoki V, Rivitti E, Eaton DP, Lin MS, Diaz LA. Endemic pemphigus foliaceus (fogo selvagem) - 1998. The Cooperative Group on Fogo Selvagem Research. Clin Dermatol. 1999;17:225–235.
    1. Counter CE. The disease called wildfire. Arch Dermatol. 1959;80:391–397.
    1. Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (Fogo selvagem): II. Current and historic epidemiologic studies. J Invest Dermatol. 1989;92:4–12.
    1. Robledo MA, Prada S, Jaramillo D, Leon W. South American pemphigus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986. Br J Dermatol. 1988;118:737–744.
    1. Campos JA. Pênfigo foliáceo (fogo selvagem). Aspectos clínicos e epidemiológicos. São Paulo: Companhia Melhoramentos; 1942. 127p
    1. Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, et al. Comparative epidemiologic of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995;104:302–305.
    1. Hans-Filho G, dos Santos V, Katayama JH, Aoki V, Rivitti EA, Sampaio SA, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol. 1996;107:68–75.
    1. Aoki V, Millikan RC, Rivitti EA, Hans-Filho G, Eaton DP, Warren SJ, et al. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem) J Investig Dermatol Symp Proc. 2004;9:34–40.
    1. Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, et al. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to fogo selvagem. J Invest Dermatol. 2004;123:1045–1051.
    1. Rivitti EA, Aoki V, Hans-Filho G, Vargas JH, Diaz LA. Tyring SK, Lupi O, Hengge UR. Tropical Dermatology. China: Elsevier Churchill Livingstone; 2006. Fogo Selvagem (endemic pemphigus foliaceus) pp. 421–427.
    1. Qian Y, Jeong JS, Maldonado M, Valenzuela JG, Gomes R, Teixeira C, et al. Cutting Edge: Brazilian Pemphigus Foliaceus Anti-Desmoglein 1 Autoantibodies Cross- React with Sand Fly Salivary LJM11 Antigen. J Immunol. 2012;189:1535–1539.
    1. Marsden RA, Vanhegan RI, Walshe M, Hill H, Mowat AG. Pemphigus foliaceus induced by penicillamine. Br Med J. 1976;2:1423–1424.
    1. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455–457.
    1. Moraes ME, Fernandez-Vina M, Lazaro A, Diaz LA, Filho GH, Friedman H, et al. An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue Antigens. 1997;49:35–40.
    1. Piovezan BZ, Petzl-Erler ML. Both qualitative and quantitative genetic variation of MHC class II molecules may influence susceptibility to autoimmune diseases: The case of endemic pemphigus foliaceus. Hum Immunol. 2013;74:1134–1140.
    1. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869–877.
    1. Aoki V, Rivitti EA, Diaz LA, Cooperative Group on Fogo Selvagem Research Update on fogo selvagem, an endemic form of pemphigus foliaceus. J Dermatol. 2015;42:18–26.
    1. Di Zenzo G, Zambruno G, Borradori L. Endemic Pemphigus Foliaceus: Towards Understanding Autoimmune Mechanisms of Disease Development. J Invest Dermatol. 2012;132:2499–2502.
    1. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest. 1992;90:919–926.
    1. Evangelista F, Roth AJ, Prisayanh P, Temple BR, Li N, Qian Y, et al. Pathogenic IgG4 autoantibodies from endemic pemphigus foliaceus recognize a desmoglein-1 conformational epitope. J Autoimmun. 2018;89:171–185.
    1. Culton DA, Qian Y, Li N, Rubenstein D, Aoki V, Filhio GH, et al. Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: A paradigm of human autoimmunity. J Autoimmun. 2008;31:311–324.
    1. Hans-Filho G, Aoki V, Bittner NRH, Bittner GC. Fogo selvagem: endemic pemphigus foliaceus. An Bras Dermatol. 2018;93:638–650.
    1. Waschke J. The desmosome and pemphigus. Histochem Cell Biol. 2008;130:21–54.
    1. Beutner EH, Prigenzi LS, Hale W, Leme Cde A, Bier OG. Immunofluorescent studies of autoantibodies to intercellular areas of epithelia in Brazilian Pemphigus Foliaceus. Proc Soc Exp Biol Med. 1968;127:81–86.
    1. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol. 2005;14:861–875.
    1. van der Wier G, Jonkman MF, Pas HH, Diercks GF. Ultrastructure of acantholysis in pemphigus foliaceus re-examined from the current perspective. Br J Dermatol. 2012;167:1265–1271.
    1. Roscoe JT, Diaz L, Sampaio SA, Castro RM, Labib RS, Takahashi Y, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol. 1985;85:538–541.
    1. Warren SJ, Lin MS, Giudice GJ, Hoffmann RG, Hans-Filho G, Aoki V, et al. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. N Engl J Med. 2000;343:23–30.
    1. Warren SJ, Arteaga LA, Rivitti EA, Aoki V, Hans-Filho G, Qaqish BF, et al. The Role of Subclass Switching in the Pathogenesis of Endemic Pemphigus Foliaceus. J Invest Dermatol. 2003;120:104–108.
    1. Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem) J Exp Med. 2003;197:1501–1510.
    1. Yoshida K, Ishii K, Shimizu A, Yokouchi M, Amagai M, Shiraishi K, et al. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to incrase blistering by p38MAPK-dependent desmoglein 1 clustering. J Dermatol Sci. 2017;85:197–207.
    1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012;45:7–35.
    1. Diaz LA, Prisayanh PS, Dasher DA, Li N, Evangelista F, Aoki V, et al. The IgM anti-desmoglein 1 response distinguishes Brazilian pemphigus foliaceus (fogo selvagem) from other forms of pemphigus. J Invest Dermatol. 2008;128:667–675.
    1. Qaqish BF, Prisayanh P, Qian Y, Andraca E, Li N, Aoki V, et al. Development of na IgG4-based predictor of endemic pemphigus foliaceus (fogo selvagem) J Invest Dermatol. 2009;129:110–118.
    1. Hilario-Vargas J, Dasher DA, Li N, Aoki V, Hans-Filho G, dos Santos V, et al. Prevalence of anti-desmogleina-3 antibodies in endemic regions of fogo selvagem in Brazil. J Invest Dermatol. 2006;126:2044–2048.
    1. Rocha-Rodrigues DB, Paschoini G, Pereira SA, dos Reis MA, Teixeira Vde P, Rodrigues Júnior V. High levels of interleukin-1 in patiens with endemic pemphigus foliaceus. Clin Diagn Lab Immunol. 2003;10:741–743.
    1. Chriguer RS, Roselino AM, de Castro M. Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus. J Clin Immunol. 2012;32:786–793.
    1. López-Robles E, Avalos-Díaz E, Vega-Memije E, Hojyo-Tomoka T, Villalobos R, Fraire S, et al. TNF-a end IL-6 are mediator in the blisterin process of pemphigus. Int J Dermatol. 2001;40:185–188.
    1. Timóteo RP, Silva MV, da Silva DAA, Catarino JDS, Alves FHC, Rodrigues Júnior V, et al. Cytokine and chemokines alterations in the form of pemphigus folicaceus (fogo selvagem) Front Immunol. 2017;8:978–978.
    1. Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th 17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci. 2009;53:228–231.
    1. Juneja M. Nikolsky's sign revisited. Journal of Oral Science. 2008;50:213–214.
    1. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405–412.
    1. Avalos-Díaz E, Olague-Marchan M, López-Swiderski A, Herrera-Esparza R, Díaz LA. Transplacental passage of maternal pemphigus foliaceus autoantibodies induces neonatal pemphigus. J Am Acad Dermatol. 2000;43:1130–1134.
    1. Zhao CY, Chiang YZ, Murrell DF. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol. 2016;33:367–374.
    1. Lin L, Zeng X, Chen Q. Pemphigus and pregnancy. Saudi Med J. 2015;36:1033–1038.
    1. Lorente Lavirgen AI, Bernabeu-Wittel J, Dominguez-Cruz J, Conejo-Mir J. Neonatal pemphigus foliaceus. J Pediatr. 2012;161:768–768.
    1. Payne AS, Stanley JR. Pemphigus. In: Goldsmith LA, Katz SI, Gilchrest BA, Peller AS, Lefflell DJ, Wolf K, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. Vol. 1. New York: McGraw Hill; 2012. pp. 586–586.
    1. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16:393–397.
    1. Arbache ST, Nogueira TG, Delgado L, Miyamoto D, Aoki V. Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience. An Bras Dermatol. 2014;89:885–889.
    1. Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30:84–94.
    1. Mutasim DF. Management of autoimmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol. 2004;51:859–877.
    1. Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302:241–253.
    1. . Hertl M, Geller S. Inicial management of pemphigus vulgaris and pemphigus foliaceus. Mar, 2017. [2018 Jun 08]. Available from: .
    1. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia Univ Press; 1949. pp. 196–196.
    1. Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clin Dermatol. 2012;30:108–113.
    1. Sebaratnam DF, Murrell DF. Objective scoring systems for disease activity in autoimmune bullous disease. Dermatol Clin. 2011;29:515-20, xi.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel